Depot-leuprolide acetate for treatment of paraphilias: a report of twelve cases

Arch Sex Behav. 2001 Aug;30(4):409-22. doi: 10.1023/a:1010213432606.


A new class of antiandrogen medications, gonadotropin-releasing hormone agonists, offers promise in the treatment of the paraphilias, with substantially less side effects than medroxyprogesterone acetate or cyproterone acetate. This paper reports the results of treatment using a depot suspension of leuprolide acetate on 12 patients with paraphilic disorders or with sexual disorders not otherwise specified to suppress or help these individuals control their deviant sexual behavior or impulses. The method involved uncontrolled observations of individuals treated with depot-leuprolide acetate for various lengths of time, from 6 months to 5 years, with the follow-up intervals ranging from 6 months to 6 years. Leuprolide acetate resulted in a significant suppression of deviant sexual interests and behavior as measured by self-report and was well tolerated. However, the three patients who were on long-term therapy developed bone demineralization, suggesting that this is a significant side effect of prolonged therapy. Leuprolide acetate shows promise as a treatment for the paraphilias.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Androgen Antagonists / adverse effects
  • Androgen Antagonists / therapeutic use*
  • Bone Resorption / chemically induced
  • Delayed-Action Preparations
  • Follicle Stimulating Hormone / metabolism
  • Follow-Up Studies
  • Humans
  • Leuprolide / adverse effects
  • Leuprolide / therapeutic use*
  • Luteinizing Hormone / metabolism
  • Male
  • Middle Aged
  • Paraphilic Disorders / drug therapy*
  • Testosterone / metabolism


  • Androgen Antagonists
  • Delayed-Action Preparations
  • Testosterone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Leuprolide